SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : MEDX ... anybody following?
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: nigel bates who wrote (746)10/8/2003 1:53:26 PM
From: Icebrg  Read Replies (1) of 2240
 
>>why put money into mAb-development if they think small molecules can do the job?

That could apply to any target. You know the arguments better then I do, I think.>>

I tend to look at mAbs as a quick and dirty way to get something into the clinic. Once a target has been identified it shouldn't be too difficult to raise some mAbs against it.

To find the right small molecule seems to be more difficult and will take longer time. It is therefore natural to start with a mAb and later to try to find the right small molecule. But if they in this case have product candidates available representing both types of compounds, it is strange that they want to proceed with the mAb.

As we have seen with the tyrosine kinase inhibitors, mAbs and small molecules aimed at the same target may have different modes of action, but still. As OGS is local to you (I suppose) I thought you might have had some insight into their choice of weapon.

Erik
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News